艾威药业（珠海）有限公司于2019年1月7日注册于珠海市横琴新区环岛东路1889号创意谷，公司注册资金1000万元，主要致力于局部外用药（眼科、鼻科）创新药的开发与注册申报。公司在美国宾夕法尼亚州的宾夕法尼亚生物技术中心有海外研发部，拥有眼药制药专家和眼科临床医生团队，负责创新制剂开发和项目管理。公司在研新药项目IVIEW-1201为治疗病毒性和细菌性结膜炎的广谱缓释产品。该项目于2016年获得了美国NIH 30万美金资助奖金；2017年11月，该项目已获得美国FDA二期临床准入批复，2018年12月31日获得美国FDA的IND批准，2019年*季度启动国际临床多中心试验。IVIEW Therapeutics Inc. (Cranbury, NJ) is a clinical stage pharmaceutical company committed to developing therapies fclear vision healthy lives. We are developing innovative therapeutics to fulfill the unmet medical needs in the ophthalmology fields. We are building a solid product pipeline through in-house innovation R&D, global co-development in-licensing. IVIEW has initiated development opportunities in cell & gene therapy in collaboration with well-known research institutions. The innovative technologies hold the promise to treat a wide array of diseases restore vision.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
